Vivani Medical completed the merger with Nano Precision Medical in a $188m deal.

Vivani Medical, a developer of implantable visual prosthetics, completed the merger with Nano Precision Medical, a biopharmaceutical business, in a $188m deal. “The completion of the merger marks a significant milestone for Vivani as we continue to grow the company with a strong team, sufficient funding, and an attractive group of investors who support our pursuit to develop and commercialize a new portfolio of miniaturized drug implants which can effectively address medication non-adherence, a major challenge in the treatment of chronic disease, including Type II diabetes. We are also committed to identifying a sustainable path forward to bring Second Sight’s Orion Visual Cortical Prosthesis System to individuals who are blind due to a wide range of causes,” Adam Mendelsohn, Nano Precision CEO. On July 29, Vivani Medical announced shareholder approval for proposed merger with Nano Precision Medical. On August 30, in connection with the merger, Second Sight changed its name to Vivani Medical.